Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Growth Hormone Deficiency Clinical Trial

Official title:

A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02418767
• Other study ID #: CP-4-007
• Status: Completed
• Phase: Phase 1
• Start date: January 2015
• Est. completion date: June 2015

Study information

• Verified date: September 2019
• Source: OPKO Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is a Phase 1, randomized, double-blind, vehicle-controlled, single-dose, three dose levels study in healthy Caucasian and Japanese male volunteers.

Following a 4-week screening period, eligible male subjects will be stratified by ethnic group and will be randomized to one of six groups. On dosing day, designated as Day 1, each subject will receive single SC injection of study medication according to group allocation and will be followed up for a month for safety monitoring.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: June 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Healthy male volunteers, 18 to 45 years of age (inclusive).

2. Body Mass Index (BMI) 18 to 30 kg/m2 (inclusive) and weighing at least 55 kg.

3. Subjects in generally good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.

4. Blood pressure and heart rate within normal limits.

5. Electrocardiogram (ECG) with no clinically significant abnormalities recorded at screening visit (up to 28 days before dosing) and on dosing day (before drug administration).

6. Negative HIV, hepatitis B and hepatitis C serology tests at screening

7. No clinically significant abnormalities in complete blood count (CBC), international normalized ratio (INR), chemistry lab tests (liver and renal function) and urinalysis at screening.

8. No history of alcohol or drug abuse within 1 year of screening. Negative urine drugs-of-abuse (DOA) in screening and on admission. Negative breath alcohol on admission.

9. Subjects must agree to use medically accepted form of contraception from dosing day to 12 weeks after drug administration.

10. Subjects must be able to understand the requirements of the study and must be willing to comply with the requirements of the study and to provide their written informed consent to participate in the study.

Exclusion Criteria:

1. History of significant neurological (including history of seizures or EEG abnormalities), renal, cardiovascular (including known structural cardiac abnormalities or hypertension), respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety, tension or agitation) or any other clinically significant medical disorder, which in the investigator's judgment contraindicate administration of the study medication.

2. Known allergy to growth hormone or any constituents or ingredients or components in the vehicle.

3. Adherence (for whatever reason) to an abnormal diet (including any dietary restrictions, e.g. low fat, lactose-free, low sodium, high protein, gluten-free, organic, etc.) during the 4 weeks prior to the study, or subjects with recent significant change in body weight.

4. Use of any prescription or over-the-counter (OTC) medications, including vitamins and herbal or dietary supplements within 14 days prior to dosing. Brief use of OTC medications for symptomatic relief of pain until 24 hours prior to and 48 hours after the study drug administration may be allowed per the discretion of the medical monitor.

5. Subjects who have received any vaccines within 4 weeks prior to study drug administration.

6. Subjects who donated blood or received blood or plasma derivatives in the one month preceding signing of consent form.

7. Systemic corticosteroids other than in replacement doses within the 3 months before study entry (temporary adjustment of glucocorticoids, as appropriate, is acceptable)

8. Anabolic steroids other than gonadal steroid replacement therapy within 2 months before study entry

9. Participation in another clinical trial with drugs within one month of signing of consent form (calculated from the previous study's last dosing date).

10. Subjects with an inability to communicate well with the investigators and clinic staff [i.e., language problem (except Japanese speakers), poor mental development or impaired cerebral function].

11. Subjects with any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator. Use of investigational products (within 30 days of screening visit).

Related Conditions & MeSH terms

• Growth Hormone Deficiency

Intervention

Drug:
• MOD-4023

• Placebo

Locations

Country	Name	City	State
United States	WCCT Global	Cypress	California

Sponsors (2)

Lead Sponsor	Collaborator
OPKO Health, Inc.	WCCT Global

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions	To assess the safety, tolerability and immunogenicity of MOD-4023 in healthy Caucasian and Japanese subjects after single subcutaneous (SC) dose.	30 days
Primary	Pharmacokinetics (PK) profile of MOD-4023 in healthy Caucasian and Japanese subjects after single SC dose	MOD-4023 serum levels (T1/2, Area-Under-the-Curve, Cmax, Tmax)	7 days
Secondary	Pharmacodynamic (PD) profile (IGF-1 and IGFBP-3 levels) to MOD-4023 in healthy Caucasian and Japanese subjects after single SC dose	IGF-1 and IGFBP-3 serum levels (T1/2, AUC, Cmax, Tmax)	14 days